TY - JOUR
T1 - Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors
AU - Chiyonobu, Norimichi
AU - Shimada, Shu
AU - Akiyama, Yoshimitsu
AU - Mogushi, Kaoru
AU - Itoh, Michiko
AU - Akahoshi, Keiichi
AU - Matsumura, Satoshi
AU - Ogawa, Kosuke
AU - Ono, Hiroaki
AU - Mitsunori, Yusuke
AU - Ban, Daisuke
AU - Kudo, Atsushi
AU - Arii, Shigeki
AU - Suganami, Takayoshi
AU - Yamaoka, Shoji
AU - Ogawa, Yoshihiro
AU - Tanabe, Minoru
AU - Tanaka, Shinji
N1 - Publisher Copyright:
© 2018 American Society for Investigative Pathology
PY - 2018/5
Y1 - 2018/5
N2 - Metabolic syndrome is a newly identified risk factor for hepatocellular carcinoma (HCC); however, tumor-specific biomarkers still remain unclear. We performed cross-species analysis to compare gene signatures of HCC from human patients and melanocortin 4 receptor-knockout mice, which develop HCC with obesity, insulin resistance, and dyslipidemia. Unsupervised hierarchical clustering and principle component analysis of 746 differentially expressed orthologous genes classified HCC of 152 human patients and melanocortin 4 receptor-knockout mice into two distinct subgroups, one of which included mouse HCC and was causatively associated with metabolic risk factors. Nine genes commonly overexpressed in human and mouse metabolic disease-associated HCC were identified; fatty acid binding protein 4 (FABP4) was remarkably enriched in intratumoral activated hepatic stellate cells (HSCs). Subclones constitutively expressing FABP4 were established from a human HSC cell line in which expression levels of inflammatory chemokines, including IL-1A and IL-6, were up-regulated through NF-κB nuclear translocation, resulting in recruitment of macrophages. An immunohistochemical validation study of 106 additional human HCC samples indicated that FABP4-positive HSCs were distributed in tumors of 38 cases, and the FABP4-high group consisted of patients with nonviral and nonalcoholic HCC (P = 0.027) and with multiple metabolic risk factors (P < 0.001) compared with the FABP4-low group. Thus, FABP4 overexpression in HSCs may contribute to hepatocarcinogenesis in patients with metabolic risk factors by modulation of inflammatory pathways.
AB - Metabolic syndrome is a newly identified risk factor for hepatocellular carcinoma (HCC); however, tumor-specific biomarkers still remain unclear. We performed cross-species analysis to compare gene signatures of HCC from human patients and melanocortin 4 receptor-knockout mice, which develop HCC with obesity, insulin resistance, and dyslipidemia. Unsupervised hierarchical clustering and principle component analysis of 746 differentially expressed orthologous genes classified HCC of 152 human patients and melanocortin 4 receptor-knockout mice into two distinct subgroups, one of which included mouse HCC and was causatively associated with metabolic risk factors. Nine genes commonly overexpressed in human and mouse metabolic disease-associated HCC were identified; fatty acid binding protein 4 (FABP4) was remarkably enriched in intratumoral activated hepatic stellate cells (HSCs). Subclones constitutively expressing FABP4 were established from a human HSC cell line in which expression levels of inflammatory chemokines, including IL-1A and IL-6, were up-regulated through NF-κB nuclear translocation, resulting in recruitment of macrophages. An immunohistochemical validation study of 106 additional human HCC samples indicated that FABP4-positive HSCs were distributed in tumors of 38 cases, and the FABP4-high group consisted of patients with nonviral and nonalcoholic HCC (P = 0.027) and with multiple metabolic risk factors (P < 0.001) compared with the FABP4-low group. Thus, FABP4 overexpression in HSCs may contribute to hepatocarcinogenesis in patients with metabolic risk factors by modulation of inflammatory pathways.
UR - http://www.scopus.com/inward/record.url?scp=85045040740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045040740&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2018.01.012
DO - 10.1016/j.ajpath.2018.01.012
M3 - Article
C2 - 29454748
AN - SCOPUS:85045040740
SN - 0002-9440
VL - 188
SP - 1213
EP - 1224
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 5
ER -